focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTreatt Regulatory News (TET)

Share Price Information for Treatt (TET)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 490.00
Bid: 340.00
Ask: 641.00
Change: 0.00 (0.00%)
Spread: 301.00 (88.529%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 490.00
TET Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

22 Jan 2021 07:00

RNS Number : 5318M
Treatt PLC
22 January 2021
 

22 January 2021

TREATT PLC

("Treatt" or "the Group")

Trading update

Strong trading - profits expected to materially exceed market consensus

Treatt, the manufacturer and supplier of a diverse and sustainable portfolio of natural extracts and ingredients for the beverage, flavour and fragrance industries, today updates on trading since the start of its financial year ending 30 September 2021 ("FY21").

Highlights

· Strong operating performance across multiple categories and customers, with new organic revenue growth and enhanced margins from improving product mix.

· Profits for the first four months of the current financial year are expected to be ahead of Board's previous expectations for the period.

· Continued partnering with customers to develop exciting products in the fast-evolving beverages market is driving potential for further revenue and margin growth.

· Headwinds from COVID-19, the geopolitical landscape and commodity/currency risks remain.

· Overall, the Board is cautiously optimistic that the current strong momentum will result in profit before tax and exceptional items for FY21 materially exceeding the current market consensus* of £15.1m.

Trading performance

As reported in our FY20 results announcement on 24 November 2020, the Group had a strong start to the new financial year, and this has continued with the trading performance in the year to date being significantly better than expected.

The Group is performing particularly well in its citrus, health & wellness, fruit & vegetables and tea categories. Some material new business wins have been achieved including in the global alcoholic seltzer category which is continuing to grow strongly. Treatt is well positioned as a supplier of natural extracts including its sugar reduction solutions; the Group's technical expertise enables it to add significant value to customers across a growing range of applications resulting in margin expansion as well as revenue growth.

Whilst some parts of our product portfolio continue to be impacted from subdued on-trade demand due to the closure of venues in many parts of the World, this has been more than offset by increased demand from off-trade channels.

The Board considers that the strong trading momentum shown in these first few months of the current financial year will continue into H2 but is mindful that the Group faces the same uncertainties as our customers regarding the ongoing COVID-19 global pandemic, potential further lockdowns in our key markets and the volatile geopolitical landscape, with potential impacts on demand, FX rates and commodity prices. Nevertheless, the better than expected performance for the first four months of the year and the level of the order book leads the Board to be cautiously optimistic about continued growth in revenues, margins and profits for the rest of FY21, with profit before tax and exceptional items for FY21 expected to materially exceed current consensus* of £15.1m.

Daemmon Reeve, CEO, commented:

"We're encouraged by our strong trading momentum continuing into the current financial year. Performance has been positive across a number of our key categories, with particular growth in our solutions for the expanding alcoholic seltzer market, utilising our expertise in natural extracts.

"Whilst mindful of the global backdrop, we are confident that we can make further progress this year, to grow organic revenue across an increasingly global and diversified customer base who benefit from our technical expertise and value-add approach."

 

* Treatt compiled consensus of analyst forecasts for FY21 of profit before tax and exceptional items.

 

Treatt plc +44 (0)1284 702500

Daemmon Reeve Chief Executive Officer

Richard Hope Chief Financial Officer

 

Broker

Investec Bank Plc +44 (0)20 7597 5970

Patrick Robb

David Anderson

Alex Wright

 

Financial PR

MHP Communications +44 (0) 20 3128 8789

Tim Rowntree

Simon Hockridge

Catherine Chapman

 

About the Group

Treatt is a global, independent manufacturer and supplier of a diverse and sustainable portfolio of natural extracts and ingredients for the flavour, fragrance and multinational consumer product industries, particularly in the beverage sector. Renowned for its technical expertise and knowledge of ingredients, their origins and market conditions, Treatt is recognised as a leader in its field.

 

The Group employs over 300 staff in Europe, North America and Asia and has manufacturing facilities in the UK and US. Its international footprint enables the Group to deliver powerful and integrated solutions for the food, beverage and fragrance industries across the globe.

 

 

For further information about the Group, visit www.treatt.com.

 

Information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS

This announcement contains forward-looking statements that are subject to risk factors associated with, among other things, the economic and business circumstances occurring from time to time in the countries, sectors and markets in which the Group operates. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a wide range of variables which could cause actual results to differ materially from those currently anticipated. No assurances can be given that the forward-looking statements in this announcement will be realised. The forward-looking statements reflect the knowledge and information available at the date of preparation of this announcement and the Group undertakes no obligation to update these forward-looking statements. Nothing in this announcement should be construed as a profit forecast.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFLALLILFIL
Date   Source Headline
7th Mar 202210:41 amRNSNotification of Transactions of Director
16th Feb 20227:00 amRNSAppointment of Chief Financial Officer
8th Feb 20225:06 pmRNSStandard Form for notification of major holdings
28th Jan 20223:29 pmRNSResult of AGM
28th Jan 20227:00 amRNSAGM Trading Update
25th Jan 20223:50 pmRNSStandard Form for notification of major holdings
20th Jan 202212:18 pmRNSConfirmation of AGM arrangements
17th Jan 20229:36 amRNSBoard Appointments
14th Jan 20229:30 amRNSVoting Rights and Capital
20th Dec 20216:16 pmRNSNotification of Transactions of Director
16th Dec 20215:50 pmRNSNotification of Transactions of Director & PCA
14th Dec 20219:07 amRNSAnnual Report
8th Dec 20214:49 pmRNSStandard form for notification of major holdings
8th Dec 20214:46 pmRNSStandard form for notification of major holdings
6th Dec 202112:32 pmRNSNotification of Transactions of Director
6th Dec 20218:58 amRNSStandard form for notification of major holdings
1st Dec 20215:25 pmRNSBLOCK LISTING SIX MONTHLY RETURN
1st Dec 20215:20 pmRNSBLOCK LISTING SIX MONTHLY RETURN
30th Nov 20217:00 amRNSFull Year Results
26th Nov 20218:25 amRNSDirector Declaration
9th Nov 20215:11 pmRNSStandard form for notification of major holdings
18th Oct 20215:58 pmRNSStandard form for notification of major holdings
18th Oct 202110:29 amRNSStandard form for notification of major holdings
15th Oct 20214:25 pmRNSStandard form for notification of major holdings
11th Oct 20217:00 amRNSTrading Update
7th Oct 20214:07 pmRNSNotification of Transactions of a PCA
4th Oct 20214:54 pmRNSTotal Voting Rights
4th Oct 202110:30 amRNSDirector/PDMR Shareholding
21st Sep 20212:25 pmRNSChange of Registered Office
21st Sep 202111:50 amRNSDirector/PDMR Shareholding
21st Sep 20219:50 amRNSHolding(s) in Company
15th Sep 20213:02 pmRNSHolding(s) in Company
9th Sep 20219:59 amRNSStandard form for notification of major holdings
8th Sep 20215:24 pmRNSNotification of Transactions of Directors and PCA
3rd Sep 20215:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20215:38 pmRNSNotification of Transaction of Director & PCA
25th Aug 20211:20 pmRNSHolding(s) in Company
23rd Aug 20215:05 pmRNSHolding(s) in Company
18th Aug 202112:30 pmRNSDirector/PDMR Shareholding
17th Aug 20217:00 amRNSBoard Change
13th Aug 20216:25 pmRNSDirector/PDMR Shareholding
9th Aug 20211:50 pmRNSNotification of Transactions of Director
20th Jul 20215:50 pmRNSHolding(s) in Company
14th Jul 20214:17 pmRNSNotification of Transactions of a PCA
14th Jul 20214:15 pmRNSDirector/PDMR Shareholding
30th Jun 20217:00 amRNSBoard Update
24th Jun 20215:16 pmRNSHolding(s) in Company
10th Jun 202111:25 amRNSHolding(s) in Company
10th Jun 202110:00 amRNSBoard Change
1st Jun 20215:14 pmRNSBlock Listing Six Monthly Return

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.